Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,458 total articles
Expand Energy (EXE) is an actionable swing trade: the company’s hedging program and marketing income are cushioning revenue volatility from softer natural gas prices, and the stock trades at a modest valuation (P/E ~7.7, EV/EBITDA ~4.7). I prefer a long trade sized as a tactical swing over the next 45 trading days, entry at $92.00, stop at $85.00 a…
Power Solutions (PSIX) has fallen roughly 42% since my prior downgrade but still trades at uncompelling multiples given margin pressure, legal overhang and decelerating growth. I recommend a mid-term short with an entry at $48.51, a target at $36.00 and a stop at $54.00. The trade leans on fundamentals (gross margin deterioration and slowing growth…
Axon (AXON) is being upgraded to Buy. The company is growing revenue rapidly and showing improving profitability, yet the stock has retraced sharply from its 2025 highs and now trades at levels that give investors an asymmetric risk-reward over the mid term. This trade plan targets a measured pullback entry, with a clear stop and a 45-trading-day h…
Legence has shown a clear willingness to reshape its balance sheet through M&A, equity issuance and targeted debt repricing. Those moves, plus strong revenue growth and robust free cash flow, make a near-term asset sale - a la a Spartan Delta structure - a credible catalyst to quickly de-risk the balance sheet and boost the stock. This trade target…
Ameriprise (AMP) reported solid top-line growth, AUM expansion and continued cash generation, but mixed headlines around margins and AI-driven fee concerns have pressured the stock. This trade idea lays out an actionable long with precise entry, stop and target for a mid-term swing (45 trading days).
VICI Properties is trading at roughly 9.9x 2026 AFFO after a $2.0 billion buyback authorization and a raised AFFO guide to $2.47-$2.48. With portfolio occupancy at 100%, a 7.7% yield, modest leverage and multiple catalysts ahead, this is a buy-the-dip idea with a clear stop and multi-horizon targets.
Micron looks like an obvious bargain when people cite a 5x forward P/E. The reality: trailing EPS, price-to-book and EV multiples show the stock is already pricing in strong execution and sustained demand. That makes the reward asymmetric but not free. I outline a long trade with clear entry, stop and target, catalyst triggers to watch, and the ris…
Fiserv is trading well below last year's highs after a pullback; the stock screens cheap on earnings and cash-flow multiples. With $3.93B of free cash flow, an EV/EBITDA near 6.8x, and a P/E around 9x, the company can weather a near-term earnings wobble while continuing to execute on product initiatives. This trade idea lays out an entry, stop, and…
Bank7 (BSVN) is set to close its Century Financial acquisition on 11/01/2026. The deal supplies cheap core deposits that materially reduce funding stress and should be deployable into higher-yielding commercial loans in Texas and Oklahoma. At a $59.31 stock price, the market already prices solid fundamentals (PE ~13.7, ROE ~15.8%), but near-term EP…
Generac beat Q3 earnings on commercial strength driven by data-center demand, reported $2.54 adjusted EPS and $1.29B revenue, and now carries multi-billion-dollar backlog including a $2.4B Amazon supply deal. The combination of visible orders and raised margin guide supports a mid-term long trade. Entry $204.57, target $245.00, stop $188.00, hold ~…
Nano Labs (NA) is a high-risk, high-upside small-cap play trading at roughly $38M market cap. The company reported a sharp H1 2026 loss driven by crypto fair-value swings but is pivoting toward AI and Web3 infrastructure with new hardware (iPollo ClawPC A1 Mini), an MoU to explore North American AI data centers, and a sizeable BNB reserve. Technica…
Kinetik Holdings ($58.19) blends midstream durability with an attractive quarterly payout and a recovery story: 52-week low of $31.33 to a new high near $58.62, a quarterly dividend of $0.81 (5.67% yield) and improving EBITDA/cash metrics. This trade idea targets further multiple expansion and stable distributions across the next 180 trading days, …
Avnet (AVT) enters its Q1 reporting window with strong operational momentum from AI infrastructure demand, a string of revenue beats, and a valuation that still looks conservative: market cap roughly $7.6B, P/S 0.28 and EV/EBITDA 11.5. The setup is actionable now — enter at $92.50, limit downside with an $85 stop, and target $100 on a 45-trading-da…
Alkermes (ALKS) is trading off its year-to-date highs despite fresh positive Phase I data for ALKS 7290 and ongoing commercial traction for core CNS franchises. The company's valuation looks full by traditional earnings multiples, but solid free cash flow and a pipeline that can re-rate the stock make a disciplined long with a tight stop and a 180-…
Kinetik offers a high, well-covered quarterly distribution (annualized $3.24; ~5.7% yield at $58.10) and near-term upside tied to takeover chatter and solid midstream fundamentals. Valuation is mixed - a mid-teens EV/EBITDA and P/E in the low-20s but limited upside given the stock is sitting at its 52-week high. This is a defensive, income-first lo…
Nuveen New York Quality Municipal Income Fund (NAN) offers an attractive entry for income-focused traders. At $9.92, the fund yields roughly 8.7% and sits well below its 52-week high of $11.80. Technicals show neutral-to-bullish momentum while short interest and volume patterns imply the move could be underpinned by a repricing of the CEF discount.…
Harrow (HROW) trades near $30 with a market cap just over $1.1B and reaffirmed 2025 revenue guidance of $270-280M. Given the early commercial traction and growing clinical evidence behind IHEEZO and BYOOVIZ, those two drugs can plausibly underwrite the current valuation if unit growth and pricing hold. This is a measured, mid-term swing trade that …
ARK Genomic Revolution ETF (ARKG) has retraced sharply from its March lows and now trades near its 52-week high. The fund remains a concentrated, high-beta play on gene editing, diagnostics and next-gen therapeutics. Given a premium valuation, heavy short positioning and a stretched rally, we propose a mid-term swing short that targets a near-term …
ASML is pricing in strong AI-driven wafer demand, and the company’s constrained capacity through 2028 gives the stock optionality. This trade idea looks to capture a mid-term run as orders and cadence reaccelerate, while protecting capital with a tight stop. Entry $1678.53, target $1900.00, stop $1500.00.
Tenable reported another quarter of revenue and EPS upside, accelerated professional services growth, and is rolling out Tenable OPEN for AI. At ~ $51.50 and a market cap near $5.7B, the stock looks like one of the better-value plays in cyber if management can sustain subscription expansion and convert AI momentum into higher net dollar retention. …
SoFi's Q3 beat and raised guidance justify a constructive stance. Memberships and products are growing fast, management says no capital raise is needed, and margins are widening. The balance of evidence supports a long trade from $17.50 with a $14.00 stop and a $26.00 target over a 180 trading-day horizon, while remaining attentive to credit and ca…
Micron ($950.51) looks expensive on headline multiples but is backed by extraordinary cash generation, capacity tightness, and contract visibility that could sustain elevated margins. This trade idea outlines a tactical long: entry $955.00, stop $800.00, primary target $1,125.00 (mid-term), and stretch upside to prior highs if the AI cycle persists…
Cognizant (CTSH) beat Q3'26 estimates but the stock has sold off. Fundamentals - a modest P/E, healthy free cash flow and AI/financial-services tailwinds - support a mid-term buy-the-dip trade. Entry $61.92, stop $57.00, target $74.00 over ~45 trading days.
Aritzia is a lifestyle apparel name that blends aspirational styling with mass-market accessibility. We like the risk/reward to the long side: buy at $25.00 with a $36.00 target and a $20.50 stop, playing a recovery in comps and margin expansion as merchandising and distribution improvements compound over the next 180 trading days.
SK hynix reported record profitability and says DRAM/HBM capacity is effectively sold out for years. The market's AI-driven memory shortage thesis is playing out in the numbers; this trade idea proposes a long with a defined entry, stop and target for the next 180 trading days.
